Research & Development
Small Cell Lung Cancer: Page 2
Invitae launches 2 IVD cancer tests in Europe
Both tests offer comprehensive genomic profiling and companion diagnostic use for solid tumor neoplasms, including non-small cell lung cancer, in tissue biopsy and where tissue is a limiting factor.
February 15, 2022
PierianDx, Biodesix partner on lung cancer diagnostics
PierianDx will provide its interpretation technology platform for use with Biodesix's newly launched GeneStrat NGS genomic test, a blood-based tumor profiling test that detects mutations -- including EGFR, ALK, and KRAS -- in patients with non-small cell lung cancer (NSCLC).
January 18, 2022
Lucence offers expanded cfRNA version LiquidHallmark
Researchers have found that adding RNA sequencing to DNA sequencing for tissue testing yields an additional 14% of "clinically actionable alterations," Lucence said. An internal study conducted by the firm found that "out of 112 non-small cell lung cancer samples, 29 fusions were detected with a combined cfDNA and cfRNA approach in plasma, compared with 20 fusions from cfDNA alone."
January 9, 2022
Quest offers Biocept's liquid biopsy test
Biocept's Target Selector NGS Lung Panel helps with the genomic profiling of patients with advanced non-small cell lung cancer. The test helps physicians identify a potential treatment target and monitor the effectiveness of patients' treatments, according to Quest.
December 1, 2021
FDA expands use of Qiagen lung cancer mutation test
Qiagen's polymerase chain reaction (PCR) test, the Therascreen KRAS RGQ PCR kit, is a tissue-based test that identifies the KAS KRAS G12C mutation in non-small cell lung cancer; the FDA approved the test for expanded use with Amgen's sotorasib (Lumakras). KRAS is one of the most frequently occurring mutations in this type of cancer.
June 1, 2021
Universal Diagnostics touts blood-based lung cancer test
Presented at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference, the test uses methylation status measurement of the tumor-derived portion from cell-free DNA (cfDNA) in plasma for patient classification. Researchers examined plasma samples of 37 lung cancer patients and 71 asymptomatic age, gender, and smoking-history matching controls.
January 28, 2021
Quest launches long-COVID testing panels for consumers
Ohio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testing
RNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug target
Patients prefer immediate test results, even when the news is bad
Point-of-care test developer Proxim Diagnostics obtains strategic investment from BioMérieux
Quest Diagnostics offers suite of services for transplant patients and living donors
Falling lung cancer rates drive cancer decline in U.S. over past 2 decades
The report found that in 2020, the cancer death rate was down by 31% compared with 1991, including a 2.4% decrease between 2017 and 2018, the ACS reported. The findings are in line with prior reports showing cancer death rates overall dropping in recent years.
January 11, 2021
FDA clears Foundation Medicine's liquid biopsy test
FoundationOne Liquid CDx can be used as a companion diagnostic for four cancer therapies, including rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor for metastatic prostate cancer patients with BRCA1/2 mutations, and three epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer patients.
August 26, 2020
Cancer research groups partner for liquid biopsy trial
In a phase II, multicenter trial, researchers from the Canadian Cancer Trial Group will first investigate whether changes in circulating cell-free tumor DNA (ctDNA) can better predict immunotherapy response than radiographic assessments. They will then examine whether ctDNA patterns can guide treatment decisions for patients with non-small cell lung cancer.
July 29, 2020
Insurance coverage of liquid biopsies for cancer surges
The study evaluated private insurance and Medicare coverage trends for tests that identify circulating tumor DNA (ctDNA), cell-free DNA fragments shed by tumors that contain information about the tumor's genetic properties. Clinicians can use the ctDNA data from liquid biopsies to make treatment decisions.
July 9, 2020
Seoul researchers tout Guardant360 clinical results
A team from Samsung Medical Center in Seoul found that the test offers "useful prognostic information beyond actionable biomarkers" for this patient population, Guardant said in a statement.
May 31, 2020
Week in Review: CDC speaks out on antibody tests | Molecular testing for cancer patients | Blood test predicts disability from concussion
Dear LabPulse Member,
May 28, 2020
Page 2 of 4